This research offers further insight into this emerging safety signal, according to the study authors who noted in their Ophthalmology paper, Our novel, stratified analysis provides a more nuanced interpretation than previous pooled reviews, isolating a potential increased risk signal to observational data in the diabetes population only, a finding not corroborated by RCTs. These results are somewhat at odds with the narrative surrounding GLP-1 use and NAION risk that began in early 2024, but the researchers say they are confident in their methodology
Further research is needed on cardiovascular effects
Doses above 600 mcg per day are not supported by additional evidence and are generally discouraged by the HealthRX medical team pending further safety data
Side effects vary based on dosage, duration of use, individual physiology, and concurrent medications
I also thank to all of your team as they did a great job. Akif Moroglu Strategy & Business Development Director The Automotive 48V ECU Components Procurement Intelligence Study was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity